AMFI Registered MFD · ARN-130934 · Mutual fund investments are subject to market risks. CA Amit Kumar Jain · +91 93522 44475 Poornima Jain · +91 92525 44475 support@plenitude.co.in हिंदी

TTK Healthcare Limited share price

TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Foods, Protective Devices and Other segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under …Read more

WebsiteNSEहिंदी मेंBSE

HealthcareDrug Manufacturers - GeneralNSE: TTKHLTCAREISIN INE910C01018
16 Oct 2026, 3:29 PM IST₹1,035.00▲ 2.30 (0.22%)
  • Market Cap₹ 1,462 Cr.
  • Current Price₹ 1,035.00
  • High / Low₹ 1,247 / 735
  • Stock P/E19.8
  • Book Value₹ 789
  • Dividend Yield0.97 %
  • ROCE7.5 %
  • ROE6.00 %
  • Face Value₹ 10.0
More figures (10)
  • EPS (TTM)₹ 52.34
  • Price / Book1.31
  • OPM2.1 %
  • Debt / Equity0.02
  • Sales growth (5Y)6.1 %
  • Profit growth (5Y)7.2 %
  • Promoter holding75.6 %
  • EV / EBITDA14.6
  • Beta0.35
  • All-time high₹ 1,894

Price chart

Returns1M3M6MYTD1Y3Y CAGR5Y CAGR
TTKHLTCARE-2.83%+4.71%+20.97%-0.37%-8.47%-4.52%+8.84%
Nifty 50-0.31%-3.85%-4.34%-11.42%-9.53%+5.46%+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

  • TTK Healthcare Limited is in the Drug Manufacturers - General industry (Healthcare), with a market value of ₹1,462 crore.
  • It trades at 19.8 times its last 12 months' earnings and 1.3 times book value.
  • Revenue grew 6.1% a year over the last 5 years, profit 7.2% a year.
  • Return on equity was 6.0% and return on capital employed 7.5% in the latest year.
  • Debt was 0.02 times shareholders' equity.
  • The share price is 17.0% below its 52-week high and down 8.5% over one year.
  • Promoters and insiders hold about 75.6%; institutions about 3.9%.

Pros

  • Company is almost debt-free (debt is 0.02 times equity).
  • Latest quarter (Jun 2026): sales up 14% and profit up 64% from a year ago.
  • Promoters hold a large stake of 74.56%.

Cons

  • Return on equity has been low: 6.8% on average over the last 3 years.
  • Other income makes up 76% of profit before tax.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About TTK Healthcare Limited

TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Foods, Protective Devices and Other segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name…

Employees
1,384
Head office
Chennai

Peer comparison

HealthcareDrug Manufacturers - General

S.No.CompanyCMP ₹P/EMar Cap ₹ CrDiv Yld %NP Qtr ₹ CrQtr Profit Var %Sales Qtr ₹ CrQtr Sales Var %ROCE %
1.TTK Healthcare1,035.0019.81,4620.972163.6925813.757.5
2.GlaxoSmithKline Pharmaceuticals2,566.1040.743,4712.26237-9.77938-3.6955.4
3.Rubicon Research1,508.6086.924,9730.1085133.9153449.2023.6
4.Pfizer3,814.0023.717,4481.972046.636538.3122.9
5.Marksans Pharma311.0027.314,0930.29159173.8984135.6117.5
6.Sanofi Consumer Healthcare India3,548.7030.78,1852.106913.342366.7077.0
7.Senores Pharmaceuticals1,318.4046.46,0720.003155.7018035.9515.5
8.SMS Pharmaceuticals450.5040.14,2190.09212.042075.5713.7
9.Sai Parenteral's487.30168.02,1530.008—179—17.9
10.CORONA Remedies2,003.9061.6—0.4960—422—29.0
Median: 10 Co.1,413.5040.48,1850.396434.5234011.0320.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Standalone figures in ₹ crore

₹ CrJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
202186184181208198205190226204209218258
192176179169201190197178224198202207243
Operating Profit1010512788123571115
OPM %5%5%3%7%3%4%4%6%1%3%3%5%6%
15161616171818191819171817
Interest1101111111111
Depreciation3333222222222
Profit before tax21221824412323221821143029
24%26%27%25%23%26%26%26%26%4%25%26%26%
16161318321717161320112221
EPS in Rs11.0911.339.1312.9322.3512.1711.8411.439.2014.437.4515.4015.06
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Standalone figures in ₹ crore

₹ CrMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
646637599725753801857888
617602577694715767831850
Operating Profit2835223137352638
OPM %4%5%4%4%5%4%3%4%
910164863717271
Interest32353333
Depreciation1414131313899
Profit before tax19372562841088394
37%-25%25%28%25%25%20%21%
12464264063826674
EPS in Rs8.7232.8729.43452.7244.4757.7946.4852.34
Dividend Payout %2%22%17%22%

Compounded Sales Growth

5 Years:
6%
3 Years:
6%
TTM:
8%

Compounded Profit Growth

5 Years:
7%
3 Years:
-53%
TTM:
17%

Stock Price CAGR

5 Years:
9%
3 Years:
-5%
1 Year:
-8%

Return on Equity

4 Years:
22%
Last Year:
6%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ CrMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital14141414
Reserves9399871,0511,101
27232424
189183192190
Total Liabilities1,1701,2061,2811,329
80778175
CWIP9202
1,0821,1271,2001,252
Total Assets1,1701,2061,2811,329

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ CrMar 2023Mar 2024Mar 2025Mar 2026
-25-5-4-21
32282052
-12-22-18-18
Net Cash Flow-62-213
Free Cash Flow-37-15-17-27

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

RatioMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROE—67.1%6.4%7.9%6.0%
ROCE—7.0%8.6%10.3%7.5%
Operating margin—2.7%3.3%3.4%2.1%
Net margin—88.8%8.4%10.2%7.7%
Debt / equity—0.030.020.020.02
Current ratio—5.065.355.235.91
Debtor days—47424147
Inventory days—8810410798
Days payable—11611010582
Cash conversion cycle—19364363
Working capital days—433428409432

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

  • Promoters 74.56%
  • FIIs 1.95%
  • DIIs 0.12%
  • Public 23.38%
%Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters74.56%74.56%74.56%74.56%74.56%74.56%74.56%74.56%74.56%74.56%74.56%74.56%
FIIs1.85%1.87%1.90%1.90%1.90%1.89%1.90%1.89%1.90%1.86%1.95%
4.99%1.14%1.14%1.14%1.14%1.14%1.18%1.18%1.08%1.11%2.19%0.12%
20.45%22.45%22.43%22.40%22.40%22.40%22.37%22.36%22.46%22.43%21.39%23.38%
No. of Shareholders16,65117,22116,93015,76215,78015,89916,11216,13422,48123,68622,80923,993

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date
17 Jul 2026
Latest quarter
30 Jun 2026
Financial year end
31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an accountHow it works

Latest news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about TTK Healthcare Limited

What is the share price of TTK Healthcare Limited today?
TTK Healthcare Limited (TTKHLTCARE) last traded at ₹1,035.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.
What is the market cap of TTK Healthcare Limited?
About ₹1,462 crore at the latest price.
What is the P/E ratio of TTK Healthcare Limited?
About 19.8 times its earnings over the last 12 months.
Is TTK Healthcare Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy TTK Healthcare Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

  • 100% free
  • No obligation
  • Reply within 2 hours
+91
Join 2,000+ investors who plan with Plenitude
Your details are private and never shared.
WhatsApp Book free call